Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy

Open access
van der Meijden, Jan C., Kruijshaar, Michelle E., Harlaar, Laurike, Rizopoulos, Dimitris, van der Beek, Nadine A. M. E., van der Ploeg, Ans T. · 2018 · Journal of Inherited Metabolic Disease

Abstract

Objectives: Pompe disease is a progressive metabolic myopathy for which enzyme replacement therapy (ERT) was approved in 2006. While various publications have examined the effects of ERT in classic‐infantile patients and in adults, little has been published on ERT in children with non‐classic presentations. Study design: This prospective study was conducted from June 1999 to May 2015. Seventeen patients from various countries participated. Outcome measures comprised muscle function (6‐minute walk test, quick motor‐function test (QMFT)), muscle strength (hand‐held dynamometry; manual muscle testing), and lung function (FVC sitting and supine). For each outcome measure, we used linear mixed‐effects models to calculate the difference at group level between the start of therapy and 7 years of ERT. Patients’ individual responses over time were also evaluated. Results: Eleven males and six females started ERT at ages between 1.1 and 16.4 years (median 11.9 years); 82% of them carried the common c.‐32‐13T > G GAA gene variant on one allele. At group level, distance walked increased by 7.4 percentage points (p < 0.001) and QMFT scores increased by 9.2 percentage points (p = 0.006). Muscle strength scores seemed to remain stable. Results on lung function were more variable. Patients’ individual data show that the proportion of patients who stabilized or improved during treatment ranged between 56 and 69% for lung function outcomes and between 71 and 93% for muscle strength and muscle function outcomes. Conclusions: We report a positive effect of ERT in patients with childhood Pompe disease at group level. For some patients, new or personalized treatments should be considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10545-018-0166-3

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Predicted group means for motor outcomes over time. Group mean (black line) of the outcome measures and 95% prediction interval (gray area) obtained using linear mixed models. The difference (Δ) between baseline and 7 years of ERT, and the corresponding p-value, are shown on the right-hand side of the figures. Number of measurements available for analysis of the 6MWT: 199, QMFT: 296, HHD: 221, and MRC: 232. N = number of patients participating in analysis
Fig. 1 Predicted group means for motor outcomes over time. Group mean (black line) of the outcome measures and 95% prediction interval (gray area) obtained using linear mixed models. The difference (Δ) between baseline and 7 years of ERT, and the corresponding p-value, are shown on the right-hand side of the figures. Number of measurements available for analysis of the 6MWT: 199, QMFT: 296, HHD: 221, and MRC: 232. N = number of patients participating in analysisCC BY · PubMed Central
Fig. 2 Predicted mean FVC scores over time. Group mean (dark line) of the outcome measures and 95% prediction interval (gray area) obtained using linear mixed models. The difference (Δ) between baseline (dotted line) and 7 years of ERT, and the corresponding p-value, are shown on the right-hand side of the figures. The trend of FVC scores in sitting position differed for males and females. They have therefore been plotted separately in panels C and D. Number of measurements available for analysis of FVC in sitting position: 331 and of FVC in supine position: 253. N = number of patients participating in analysis
Fig. 2 Predicted mean FVC scores over time. Group mean (dark line) of the outcome measures and 95% prediction interval (gray area) obtained using linear mixed models. The difference (Δ) between baseline (dotted line) and 7 years of ERT, and the corresponding p-value, are shown on the right-hand side of the figures. The trend of FVC scores in sitting position differed for males and females. They have therefore been plotted separately in panels C and D. Number of measurements available for analysis of FVC in sitting position: 331 and of FVC in supine position: 253. N = number of patients participating in analysisCC BY · PubMed Central
Fig. 3 Individual patients’ response on the different outcome measures
Fig. 3 Individual patients’ response on the different outcome measuresCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 2

  1. 1978, Aids to the Examination of the Peripheral Nervous System, Memorandum No. 45
  2. Core Team R, 2015, R Foundation for Statistical Computing

Cited by

See all 37

Metadata

Authors
van der Meijden, J. C., Kruijshaar, M. E., Harlaar, L., Rizopoulos, D., van der Beek, N. A. M. E., & van der Ploeg, A. T.
Affiliations
  • Center for Lysosomal and Metabolic Diseases, Department of Pediatrics Erasmus MC University Medical Center Wytemaweg 80 Rotterdam 3015 CN The Netherlands
  • Erasmus MC (NL)
  • Center for Lysosomal and Metabolic Diseases, Department of Neurology Erasmus MC University Medical Center Rotterdam the Netherlands
Venue
Journal of Inherited Metabolic Disease
Publisher
Wiley
Published
2018-03-19
Volume
41
Issue
6
Pages
1205-1214
ISSN
  • 0141-8955 (ISSN-L)
  • 1573-2665
OpenAlex
W2789403551
Cited by
37
References
50
Citations by year
2026: 1 · 2025: 5 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 4
FWCI
2.74
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Inherited Metabolic Disease (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
Funders
University Medical Center Rotterdam
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
Pompe disease, enzyme replacement therapy, muscle function, muscle strength, lung function, long-term follow-up, metabolic myopathies
MeSH terms
Walk Test, Adolescent, alpha-Glucosidases, Animals, Child, Child, Preschool, Female, Follow-Up Studies, Glycogen Storage Disease Type II, Humans, Infant, Male, Prospective Studies, Rabbits, Respiratory Function Tests, Linear Models, Treatment Outcome, Internationality, Muscle Strength, Enzyme Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. https://app.cochat.ai/papers/10.1007/s10545-018-0166-3
The paper
van der Meijden, J. C., Kruijshaar, M. E., Harlaar, L., Rizopoulos, D., van der Beek, N. A. M. E., & van der Ploeg, A. T. (2018). Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. Journal of Inherited Metabolic Disease. https://doi.org/10.1007/s10545-018-0166-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.